Plus Therapeutics Inc
PSTV0.690USD
+0.105+17.95%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
11.73MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Plus Therapeutics Inc Unternehmen
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
Unternehmensinformationen
BörsenkürzelPSTV
Name des UnternehmensPlus Therapeutics Inc
IPO-datumAug 09, 2000
CEODr. Marc H. Hedrick, M.D.
Anzahl der mitarbeiter21
WertpapierartOrdinary Share
GeschäftsjahresendeAug 09
Addresse4200 Marathon Blvd.
StadtAUSTIN
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl78756
Telefon17372557194
Websitehttp://www.plustherapeutics.com/
BörsenkürzelPSTV
IPO-datumAug 09, 2000
CEODr. Marc H. Hedrick, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
29.33K
--
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.43K
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Michael Stanley Rosol, Ph.D.
Dr. Michael Stanley Rosol, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
29.33K
--
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.43K
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Mar 4
Währung: USDAktualisiert: Tue, Mar 4
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
Nach RegionUSD
Name
Umsatz
Anteil
Japan
2.06M
77.05%
Americas
293.00K
10.97%
EMEA
270.00K
10.11%
Asia Pacific
50.00K
1.87%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
Aktionärsstatistik
Aktualisiert: Fri, Jun 27
Aktualisiert: Fri, Jun 27
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Great Point Capital LLC
1.46%
S.H.N. Financial Investments Ltd
1.46%
HRT Financial LP
0.17%
Susquehanna International Group, LLP
0.13%
Geode Capital Management, L.L.C.
0.09%
Other
96.68%
Aktionäre
Aktionäre
Anteil
Great Point Capital LLC
1.46%
S.H.N. Financial Investments Ltd
1.46%
HRT Financial LP
0.17%
Susquehanna International Group, LLP
0.13%
Geode Capital Management, L.L.C.
0.09%
Other
96.68%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
1.91%
Corporation
1.46%
Individual Investor
0.24%
Investment Advisor/Hedge Fund
0.10%
Research Firm
0.07%
Hedge Fund
0.04%
Other
96.19%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
34
2.31M
3.81%
-2.38M
2025Q1
40
2.31M
11.85%
+1.40M
2024Q4
42
829.50K
14.07%
-98.90K
2024Q3
44
822.91K
13.96%
-122.82K
2024Q2
46
793.04K
13.90%
-131.21K
2024Q1
46
164.14K
3.77%
-119.25K
2023Q4
47
203.09K
4.50%
+1.47K
2023Q3
47
127.65K
2.90%
-110.39K
2023Q2
45
114.35K
4.03%
-124.09K
2023Q1
46
144.27K
6.00%
-86.09K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Great Point Capital LLC
885.45K
1.74%
--
--
Apr 18, 2025
S.H.N. Financial Investments Ltd
885.45K
1.74%
--
--
Apr 18, 2025
HRT Financial LP
102.06K
0.2%
+102.06K
--
Mar 31, 2025
Susquehanna International Group, LLP
80.50K
0.16%
+80.50K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
57.05K
0.11%
-1.10K
-1.89%
Mar 31, 2025
Petersen (Gregory B)
48.92K
0.1%
--
--
Mar 04, 2025
Virtu Americas LLC
40.03K
0.08%
+40.03K
--
Mar 31, 2025
UBS Financial Services, Inc.
33.44K
0.07%
+33.44K
--
Mar 31, 2025
The Vanguard Group, Inc.
32.54K
0.06%
--
--
Mar 31, 2025
Lenk (Robert P)
29.33K
0.06%
--
--
Apr 18, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Datum
Art
Verhältnis
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
